Back to Journals » Patient Preference and Adherence » Volume 10

Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia

Authors Jacob JA, Salmani JMM, Chen B

Received 29 March 2016

Accepted for publication 3 May 2016

Published 20 June 2016 Volume 2016:10 Pages 1115—1119

DOI https://doi.org/10.2147/PPA.S109477

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Naifeng Liu

Joe Antony Jacob, Jumah Masoud Mohammad Salmani, Baoan Chen

Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of China

Abstract: Targeted therapy has modernized the treatment of both chronic and acute lymphoblastic leukemia. The introduction of monoclonal antibodies and combinational drugs has increased the survival rate of patients. Preclinical studies with various agents have resulted in positive outputs with Phase III trial drugs and monoclonal antibodies entering clinical trials. Most of the monoclonal antibodies target the CD20 and CD22 receptors. This has led to the approval of a few of these drugs by the US Food and Drug Administration. This review focuses on the drugs under preclinical and clinical study in the ongoing efforts for treatment of acute and chronic lymphoblastic leukemia.

Keywords: targeted therapy, monoclonal antibodies, preclinical studies, receptors, lymphoblastic leukemia
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]